C.R. Bard
http://www.crbard.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From C.R. Bard
Samsung Bioepis’ Stelara Biosimilar Shows Long-Term Similarity In Plaque Psoriasis
Hot off the press, Samsung Bioepis reports final data for its ustekinumab biosimilar SB17 in plaque psoriasis ahead of potential US market entry early next year, and gives more data on adalimumab biosimilar Hadlima to support interchangeability.
Samsung Bioepis Achieves Ophthalmology Milestone With Korean Aflibercept Approval
Samsung Bioepis has celebrated becoming the first developer to obtain approvals for both Lucentis and Eylea biosimilars, after its SB15 aflibercept candidate was approved in Korea.
Samsung Bioepis And Sandoz Get EU Nod For Stelara Rival
Samsung Bioepis has received an EMA nod for its Sandoz-partnered Stelara biosimilar under the name Pyzchiva. Meanwhile, the agency’s CHMP also recommended granting centralized marketing authorizations for two Accord generics.
Two Avian Flu Vaccines Among 10 New Products To Get EMA Nod
The European Medicines Agency has OKd two new H5N1 jabs, including a pandemic preparedness vaccine intended for use only if a flu pandemic is declared. Eight other products are also heading for EU-wide approval.
Company Information
- Industry
- Medical Devices
- Other Names / Subsidiaries
-
- Davol, Inc.
- Embo Medical Limited
- Liberator Medical, Inc.
- Lutonix, Inc.
- Medafor, Inc.
- Medicon, Inc.
- Neomend, Inc.
- Rochester Medical, Inc.
- Vascular Pathways, Inc.
- FlowCardia, Inc.
- Bridger Biomed, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice